Most Read

  1. Pneumococcal Vaccine as One of the Immunization Coverage Targets for Adulthood Vaccines: A Consensus Report of the Study Group for Adult Immunization of the Turkish Society of Clinical Microbiology and Infectious Diseases
  2. Does Hepatitis B Affect Erectile Dysfunction and Lower Urinary Tract Symptoms?
  3. HIV Infection in Turkey: How Close Are We to the Target?
  4. Evaluation of HBeAg-Negative Chronic Hepatitis B Patients Who Had Undergone Liver Biopsy in Accordance With the Guidelines
  5. Diagnosis, Treatment and Prevention of Diabetic Foot Wounds and Infections: Turkish Consensus Report
  6. When to Stop Antiviral Therapy in Chronic Hepatitis B
  7. Mycoplasma hominis and Ureaplasma urealyticum: Their Role in Urogenital System Infections and Retrospective Evaluation of Antibiotic Resistance Rates
  8. Crimean-Congo Haemorrhagic Fever: Treatment and Use of Ribavirin
  9. Modern Diagnostic Methods Used in Bacteriology: Rapid and Effective
  10. A Case of Generalized Tetanus With a Short Incubation Period
  11. Analysis of HIV/AIDS-Related Stigma and Discrimination in Turkey: Results of the People Living With HIV Stigma Index
  12. Does Anti-HIV Positivity in Pregnancy Suggest the Requirement of HIV Prophylaxis for Newborn?

Volume 33, Issue 3

Original Article

Evaluation of the Effectiveness of Direct-Acting Antiviral Agents in Patients With Hepatitis C

Hatun Öztürk-Çerik
Affiliations
  • Ordu Devlet Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ordu, Türkiye
,
Şaban Esen
Affiliations
  • Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye
,
Betül Altıntaş-Öner
Affiliations
  • Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye
,
Merve Çelik
Affiliations
  • Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye
,
Tuğba Özdemir
Affiliations
  • Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara, Türkiye
,
Esra Tanyel
Affiliations
  • Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye
  • dasabuvir
  • hepatitis C
  • Hepntitis C
  • ledipasvir
  • ombitasvir
  • paritaprevir
  • sofosbuvir

Objective: Hepatitis C virus (HCV) infection is a global problem with personal, social and economic impacts. Approximately 85% of patients infected with HCV cannot achieve virus clearance. Cirrhosis, hepatocellular carcinoma and death may develop in patients with chronic infection.Until recently, treatments for chronic hepatitis C were difficult to use with many side effects, low treatment responses, and relapses. Direct-acting antivirals (DAAs) prevent HCV replication, and thir effectiveness is over 90%. In this study, we aimed to evaluate the achievement of these treatments.

Methods: Fifty patients who would receive a DAA treatment regimen, i.e. sofosbuvir/ledipasvir (SOF/LDV) ± ribavirin (RBV) or paritaprevir/ritonavir/ombitasvir/dasabuvir (PrOD) ± RBV were included in the study. Laboratory values and HCV RNA results of all patients were evaluated before, at the 12th week and 24th week of treatment (at the 36th week for those who received 24 weeks of treatment), and aspartate aminotransferase (AST) to platelet ratio index (APRI), Fibrosis-4 (FIB-4), model for end-stage liver disease (MELD) scores were calculated.

Results: In 47 of 50 patients included in the study, who sustained viral response (SVR-12) could be evaluated at week 12, and HCV RNA was found negative in all patients evaluated. None of the patients had any side effects requiring discontinuation, and the most common side effect was weight gain.There was a significant decrease in AST and alanin aminotransferase (ALT) compared to their initial values.The calculated FIB-4 and APRI scores of the patients decreased significantly at the end of the treatment and in the SVR-12 period.

Conclusions: DAAs used in the treatment of HCV infection provide a high rate of SVR without any significant side effects.

Klimik Dergisi 2020; 33(3): 297-306.

Cite this article as: Öztürk-Çerik H, Esen Ş, Altıntaş-Öner B, Çelik M, Özdemir T, Tanyel E. [Evaluation of the effectiveness of direct-acting antiviral agents in patients with hepatitis C]. Klimik Derg. 2020; 33(3): 297-306. Turkish.

  • 297-306
  • 10.5152/kd.2020.60
  • December 31, 2020
  • 751
  • 495
Download as PDF
  • This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. CC BY-NC
Volume 37, Issue 3 Volume 37, Issue 2 Volume 37, Issue 1 Volume 36, Issue 4 Volume 36, Supplement 1 Volume 36, Issue 3 Volume 36, Issue 2 Volume 36, Issue 1 Volume 35, Issue 4 Volume 35, Issue 3 Volume 35, Issue 2 Volume 35, Issue 1 Volume 34, Issue 3 Volume 34, Issue 2 Volume 34, Issue 1 Volume 33, Issue 3 Volume 33, Issue 2 Volume 33, Issue 1 Volume 32, Issue 3 Volume 32, Supplement 1 Volume 32, Supplement 2 Volume 32, Issue 2 Volume 32, Issue 1 Volume 31, Issue 3 Volume 31, Issue 2 Volume 31, Supplement 1 Volume 31, Issue 1 Volume 30, Issue 3 Volume 30, Issue 2 Volume 30, Supplement 1 Volume 30, Issue 1 Volume 29, Issue 3 Volume 29, Issue 2 Volume 29, Issue 1 Volume 28, Supplement 1 Volume 28, Issue 3 Volume 28, Issue 2 Volume 28, Issue 1 Volume 27, Supplement 1 Volume 27, Issue 3 Volume 27, Issue 2 Volume 27, Issue 1 Volume 26, Issue 3 Volume 26, Supplement 1 Volume 26, Issue 2 Volume 26, Issue 1 Volume 25, Issue 3 Volume 25, Issue 2 Volume 25, Issue 1 Volume 24, Issue 3 Volume 24, Issue 2 Volume 24, Issue 1 Volume 23, Issue 3 Volume 23, Issue 2 Volume 23, Issue 1 Volume 22, Issue 3 Volume 22, Issue 2 Volume 22, Issue 1 Volume 21, Issue 3 Volume 21, Supplement 2 Volume 21, Supplement 1 Volume 21, Issue 2 Volume 21, Issue 1 Volume 20, Issue 3 Volume 20, Supplement 2 Volume 20, Issue 2 Volume 20, Issue 1 Volume 20, Supplement 1 Volume 19, Issue 3 Volume 19, Issue 2 Volume 19, Issue 1 Volume 18, Issue 3 Volume 18, Supplement 1 Volume 18, Issue 2 Volume 18, Issue 1 Volume 17, Issue 3 Volume 17, Issue 2 Volume 17, Issue 1 Volume 16, Issue 3 Volume 16, Issue 2 Volume 16, Issue 1 Volume 1, Supplement 1 Volume 15, Issue 3 Volume 15, Issue 2 Volume 15, Issue 1 Volume 14, Issue 3 Volume 14, Issue 2 Volume 14, Issue 1 Volume 13, Issue 3 Volume 13, Issue 2 Volume 13, Supplement 1 Volume 13, Issue 1 Volume 12, Issue 3 Volume 12, Issue 2 Volume 12, Issue 1 Volume 11, Issue 3 Volume 11, Issue 2 Volume 11, Supplement 1 Volume 11, Issue 1 Volume 10, Issue 3 Volume 10, Issue 2 Volume 10, Issue 1 Volume 9, Issue 3 Volume 9, Issue 2 Volume 9, Issue 1 Volume 8, Issue 3 Volume 8, Issue 2 Volume 8, Issue 1 Volume 6, Issue 3 Volume 7, Issue 1 Volume 7, Issue 2 Volume 7, Issue 3 Volume 4, Issue 3 Volume 5, Issue 1 Volume 5, Issue 2 Volume 5, Issue 3 Volume 6, Issue 1 Volume 6, Issue 2 Volume 3, Issue 1 Volume 3, Issue 2 Volume 3, Issue 3 Volume 4, Issue 1 Volume 4, Issue 2 Volume 1, Issue 2 Volume 2, Issue 1 Volume 2, Issue 2 Volume 2, Issue 3 Volume 1, Issue 1